Bevacizumab-based therapy in relapsed glioblastoma: Rationale and clinical experience to date

Expert Review of Anticancer Therapy

Volumn 12, Issue 11, 2012, Pages 1413-1427

  Chinot, Olivier L ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

angiogenesis; bevacizumab; glioblastoma; irinotecan; VEGF

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CORTICOSTEROID; ENZASTAURIN; ENZYME INDUCING AGENT; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; NITROSOUREA; PAZOPANIB; PROCARBAZINE; STEROID; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN;

ADD ON THERAPY; ANTIANGIOGENIC THERAPY; APHASIA; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BLEEDING; BLOOD TOXICITY; BRAIN ISCHEMIA; CANCER RECURRENCE; COGNITIVE DEFECT; COLITIS; CONFUSION; CONVULSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEMORRHOID HEMORRHAGE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGNOSIS; PROTEINURIA; PYRAMIDAL SIGN; REVIEW; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871259932     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.128     Document Type: Review

References (92)

1. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg. Focus 20(4), E5 (2006).
2. Ohgaki H. Epidemiology of brain tumors. Methods Mol. Biol. 472, 323-342 (2009).
3. Stupp R, Hegi ME, Mason WP et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
4. Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28(24), 3838-3843 (2010).
5. Stupp R, Wong ET, Kanner AA et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised Phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192-2202 (2012).
6. Franceschi E, Tosoni A, Girardi F, Brandes AA. Bevacizumab in brain tumors: ready for primetime? Future Oncol. 5(8), 1183-1184 (2009).
7. Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr. Opin. Neurol. 22(6), 657-664 (2009).
8. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
9. Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro-oncology 9(1), 29-38 (2007).
10. Lamborn KR, Yung WK, Chang SM et al.; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncology 10(2), 162-170 (2008).
11. Kong DS, Lee JI, Kim JH et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-oncology 12(3), 289-296 (2010).
12. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the 'rescue' approach. Cancer 113(8), 2152-2157 (2008).
13. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J. Neurooncol. 103(3), 585-593 (2011).
14. Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27(8), 1262-1267 (2009).
15. Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 256(5), 734-741 (2009).
16. Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J. Neurooncol. 104(3), 639-646 (2011).
17. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
18. Anderson JC, McFarland BC, Gladson CL. New molecular targets in the angiogenic vessels of glioblastoma tumors. Expert Rev. Mol. Med. 10, e23 (2009).
19. Brastianos PK, Batchelor T. VEGF inhibitors in brain tumours. Clin. Adv. Haem. Oncol. 7(11), 753-768 (2009).
20. Wong ET, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J. Natl Compr. Canc. Netw. 6(5), 515-522 (2008).
21. Oka N, Soeda A, Inagaki A et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem. Biophys. Res. Commun. 360(3), 553-559 (2007).
22. Batchelor T, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817-2823 (2010).
23. Batchelor T, Mulholland P, Neyns B et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro. Oncol. 12(Suppl. 4), iv69-iv78 (2010).
24. Frentzas SN, Groves MD, Barriuso J et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study. J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 2040).
25. Neyns B, Sadones J, Chaskis C et al. Phase II trial of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 103, 491-501 (2011).
26. Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr. Opin. Oncol. 22(6), 586-591 (2010).
27. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
28. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
29. Wefel JS, Cloughesy T, Zazzali JL et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncology 13(6), 660-668 (2011).
30. Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12), 1329-1334 (2010).
31. Reardon DA, Galanis E, DeGroot JF et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neurooncology 13(3), 353-361 (2011).
32. Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010).
33. Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J. Neurooncol. 96(2), 259-269 (2010).
34. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J. Natl Compr. Canc. Netw. 9(4), 403-407 (2011).
35. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
36. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised Phase-III NO16966 trial. Br. J. Cancer 101(7), 1033-1038 (2009).
37. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27(8), 1227-1234 (2009).
38. Prados MD, Lamborn K, Yung WK et al.; North American Brain Tumor Consortium. A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology 8(2), 189-193 (2006).
39. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. World Federation of Neuro-Oncology 2nd Quadrennial Meeting 2005. Neuro. Oncol. 7, 369 (2005) (Abstract 342).
40. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
41. Grude F, Campone M, Frenel J et al. Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2086).
42. Tabouret E, Barrie M, Boucard C et al. Functional and survival effect of bevacizumab and irinotecan administered at recurrence in a cohort of patients with GBM. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2087).
43. Hofer S, Elandt K, Greil R et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 50(5), 630-635 (2011).
44. Maron R, Vredenburgh JJ, Desjardins A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 2074).
45. Verhoeff JJ, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 21(8), 1723-1727 (2010).
46. Rich JN, Desjardins A, Sathronsumetee S et al. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 2022).
47. Soffietti R, Trevisan E, Ruda R et al. Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2027).
48. Francesconi AB, Dupre S, Matos M et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci. 17(8), 970-974 (2010).
49. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-oncology 12(12), 1300-1310 (2010).
50. Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-oncology 11(5), 550-555 (2009).
51. Reardon DA, Vredenburgh JJ, Desjardins A et al. Bevacizumab (BV) continuation following BV progression: meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2030).
52. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217-1222 (2009).
53. Mammoser AG, Shonka NA, DeGroot JF. Modulating bevacizumab resistance: an alternative dosing strategy at progression. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract e12500).
54. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 156-163 (2009).
55. Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncology 13(1), 143-151 (2011).
56. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8(7), 1277-1280 (1990).
57. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J. Clin. Oncol. 27(18), 2905-2908 (2009).
58. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192-2197 (2008).
59. Chang SM, Clarke J, Wen P. Novel imaging response assessment for drug therapies in recurrent malignant glioma. In: ASCO Educational Book. American Society of Clinical Oncology, VA, USA, 107-111 (2009).
60. Nowosielski M, Recheis W, Goebel G et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53(4), 291-302 (2011).
61. Fellah S, Girard N, Chinot O, Cozzone PJ, Callot V. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol. 29(11), e308-e311 (2011).
62. Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25(30), 4714-4721 (2007).
63. Wardak M, Schiepers C, Dahlbom M et al. Discriminant analysis of 18f-Fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin. Cancer. Res. 17, 6553-6562 (2011).
64. Colavolpe C, Chinot O Metellus P et al. FDG-PET predicts survival in recurrent high grade gliomas treated with bevacizumab and irinotecan. Neuro. Oncol. 14, 649-657 (2012).
65. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008).
66. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009).
67. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3), 232-239 (2009).
68. Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108(9), 3749-3754 (2011).
69. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J. Neurooncol. 101(2), 319-323 (2011).
70. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110(1), 173-180 (2009).
71. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009).
72. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S. The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. J. Clin. Oncol. 27(Suppl.) (2009) (Abstract 2057).
73. Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15), 1200-1206 (2009).
74. Narayana A, Kunnakkat SD, Medabalmi P et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 77-82 (2012).
75. Wick A, Dörner N, Schäfer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann. Neurol. 69(3), 586-592 (2011).
76. Ong SS, Puduvalli VK. Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas. J. Clin. Oncol. 28(Suppl.), 15s (2010) (Abstract 2019).
77. De Groot JF, Fuller G, Kumar A et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 12, 233-422 (2010).
78. Pope WB, Xia Q, Paton VE et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76(5), 432-437 (2011).
79. Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99(2), 237-242 (2010).
80. Bredel M. Translating biological insights into clinical endpoints in neuro-oncology. Lancet Oncol. 10(10), 928-929 (2009).
81. Anderson SK, Lafky JM, Carrero XW et al. Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2019).
82. Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2021).
83. Eoli M, Calleri A, Cuppini L et al. Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 2044).
84. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
85. Kairouz VF, Elias EF, Chahine GY et al. Final results of an extended Phase II trial of bevacizumab and irinotecan in relapsed high grade gliomas. Neuro. Oncol. 12(Suppl. 4), 40-41 (2010) (Abstract NO-20).
86. Pichler J, Buchroithner J, Nöbauer S, et al. Prospective evaluation of irinotecan and bevacizumab in recurrent malignant glioma: noticeable results of response in a poor prognostic group. Presented at: The 8th Congress of the European Association for Neuro-Oncology. Barcelona, Spain, 12-14 September 2008.
87. Gil MJ, de Las Peñas R, Reynés G et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs 23(6), 659-665 (2012).
88. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Central nervous system cancers V.2.2009. www.nccn.org/ professionals/physician-gls/ PDF/cns.pdf
89. Avastin summary of product characteristics - EU. www.ema.europa.eu/ humandocs/PDFs/ EPAR/avastin
90. Avastin (bevacizumab) for glioblastoma treatment. www.avastin.com/ avastin/patient/gbm/ index.html
91. Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda- docs/ label/2009/125085s0169lbl.pdf
92. Campto summary of product characteristics - EU. http://emc.medicines.org. uk/medicine/ 12508/SPC/Campto+40mg+2ml+and +100mg+5ml+concentrate+for+solution+for+infusion